These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

335 related items for PubMed ID: 38705930

  • 1. Novel therapeutic strategies for rare mutations in non-small cell lung cancer.
    Gou Q, Gou Q, Gan X, Xie Y.
    Sci Rep; 2024 May 05; 14(1):10317. PubMed ID: 38705930
    [Abstract] [Full Text] [Related]

  • 2. Targeted therapy for lung cancer: Beyond EGFR and ALK.
    Herrera-Juárez M, Serrano-Gómez C, Bote-de-Cabo H, Paz-Ares L.
    Cancer; 2023 Jun 15; 129(12):1803-1820. PubMed ID: 37073562
    [Abstract] [Full Text] [Related]

  • 3. Targeting the MET gene for the treatment of non-small-cell lung cancer.
    Gelsomino F, Facchinetti F, Haspinger ER, Garassino MC, Trusolino L, De Braud F, Tiseo M.
    Crit Rev Oncol Hematol; 2014 Feb 15; 89(2):284-99. PubMed ID: 24355409
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Advanced Non-Small Cell Lung Cancer: Sequencing Agents in the EGFR-Mutated/ALK-Rearranged Populations.
    Singhi EK, Horn L, Sequist LV, Heymach J, Langer CJ.
    Am Soc Clin Oncol Educ Book; 2019 Jan 15; 39():e187-e197. PubMed ID: 31099642
    [Abstract] [Full Text] [Related]

  • 7. Genomic Signature of Driver Genes Identified by Target Next-Generation Sequencing in Chinese Non-Small Cell Lung Cancer.
    Wen S, Dai L, Wang L, Wang W, Wu D, Wang K, He Z, Wang A, Chen H, Zhang P, Dong X, Dong YA, Wang K, Yao M, Wang M.
    Oncologist; 2019 Nov 15; 24(11):e1070-e1081. PubMed ID: 30902917
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged non-small cell lung cancer and beyond.
    Ou SH.
    Drug Des Devel Ther; 2011 Nov 15; 5():471-85. PubMed ID: 22162641
    [Abstract] [Full Text] [Related]

  • 10. Management and future directions in non-small cell lung cancer with known activating mutations.
    Gerber DE, Gandhi L, Costa DB.
    Am Soc Clin Oncol Educ Book; 2014 Nov 15; ():e353-65. PubMed ID: 24857124
    [Abstract] [Full Text] [Related]

  • 11. Benefit of Targeted DNA Sequencing in Advanced Non-Small-Cell Lung Cancer Patients Without EGFR and ALK Alterations on Conventional Tests.
    Byeon S, Lee B, Park WY, Choi YL, Jung HA, Sun JM, Ahn JS, Ahn MJ, Park K, Lee SH.
    Clin Lung Cancer; 2020 May 15; 21(3):e182-e190. PubMed ID: 31839532
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Resistance profiles of anaplastic lymphoma kinase tyrosine kinase inhibitors in advanced non-small-cell lung cancer: a multicenter study using targeted next-generation sequencing.
    Lin YT, Chiang CL, Hung JY, Lee MH, Su WC, Wu SY, Wei YF, Lee KY, Tseng YH, Su J, Chung HP, Lin CB, Ku WH, Chiang TS, Chiu CH, Shih JY.
    Eur J Cancer; 2021 Oct 15; 156():1-11. PubMed ID: 34392186
    [Abstract] [Full Text] [Related]

  • 14. Strategies to overcome acquired resistance to EGFR TKI in the treatment of non-small cell lung cancer.
    Gao J, Li HR, Jin C, Jiang JH, Ding JY.
    Clin Transl Oncol; 2019 Oct 15; 21(10):1287-1301. PubMed ID: 30864018
    [Abstract] [Full Text] [Related]

  • 15. Personalized targeted therapy for lung cancer.
    Wu K, House L, Liu W, Cho WCS.
    Int J Mol Sci; 2012 Oct 15; 13(9):11471-11496. PubMed ID: 23109866
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Clinical outcomes of advanced non-small-cell lung cancer patients with EGFR mutation, ALK rearrangement and EGFR/ALK co-alterations.
    Lou NN, Zhang XC, Chen HJ, Zhou Q, Yan LX, Xie Z, Su J, Chen ZH, Tu HY, Yan HH, Wang Z, Xu CR, Jiang BY, Wang BC, Bai XY, Zhong WZ, Wu YL, Yang JJ.
    Oncotarget; 2016 Oct 04; 7(40):65185-65195. PubMed ID: 27533086
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. EGFR and EML4-ALK Updated Therapies in Non-Small Cell Lung Cancer.
    De Mello RA, Liu DJ, Aguiar PN, Tadokoro H.
    Recent Pat Anticancer Drug Discov; 2016 Oct 04; 11(4):393-400. PubMed ID: 27491402
    [Abstract] [Full Text] [Related]

  • 20. Drug resistance of targeted therapy for advanced non-small cell lung cancer harbored EGFR mutation: from mechanism analysis to clinical strategy.
    Zhao Y, Wang H, He C.
    J Cancer Res Clin Oncol; 2021 Dec 04; 147(12):3653-3664. PubMed ID: 34661758
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.